Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment

Abstract

Although gemcitabine monotherapy is the standard treatment for advanced pancreatic cancer, patient outcome varies significantly, and a considerable number do not benefit adequately. We therefore searched for new biomarkers predictive of overall patient survival. Using LC-MS, we compared the base-line plasma proteome between 29 representative patients with advanced pancreatic cancer who died within 100 days and 31 patients who survived for more than 400 days after receiving at least two cycles of the same gemcitabine monotherapy. Identified biomarker candidates were then challenged in a larger cohort of 304 patients treated with the same protocol using reverse-phase protein microarray. Among a total of 45,277 peptide peaks, we identified 637 peaks whose intensities differed significantly between the two groups (p < 0.001, Welch's t test). Two MS peaks with the highest statistical significance (p ‫؍‬ 2.6 ؋ 10 ؊4 and p ‫؍‬ 5.0 ؋ 10 ؊4) were revealed to be derived from ␣ 1 -antitrypsin and ␣ 1 -antichymotrypsin, respectively. The levels of ␣ 1 -antitrypsin (p ‫؍‬ 8.9 ؋ 10 ؊8) and ␣ 1 -antichymotrypsin (p ‫؍‬ 0.001) were significantly correlated with the overall survival of the 304 patients. We selected ␣ 1 -antitrypsin (p ‫؍‬ 0.0001), leukocyte count (p ‫؍‬ 0.066), alkaline phosphatase (p ‫؍‬ 8.3 ؋ 10 ؊8 ), and performance status (p ‫؍‬ 0.003) using multivariate Cox regression analysis and constructed a scoring system (nomogram) that was able to identify a group of high risk patients having a short median survival time of 150 days (95% confidence interval, 123-187 days; p ‫؍‬ 2.0 ؋ 10 ؊15 , log rank test). The accuracy of this model for prognostication was internally validated and showed good calibration and discrimination with a bootstrap-corrected concordance index of 0.672. In conclusion, an increased level of ␣ 1 -antitrypsin is a biomarker that predicts short overall survival of patients with advanced pancreatic cancer receiving gemcitabine monotherapy. Although an external validation study will be necessary, the current model may be useful for identifying patients unsuitable for the standardized therapy. Molecular & Cellular Proteomics 9:695-704, 2010.

Reduced Plasma Level of CXC Chemokine Ligand 7 in Patients with Pancreatic Cancer

“…The reproducibility of the reverse-phase protein microarray assay was determined by repeating the same experiment, as reported previously (28). A plasma sample after reduction of the 12 most abundant plasma proteins was serially diluted within a range of 25-to 6,400-fold.…”

Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray

“…All intensity values were transformed into logarithmic variables. The reproducibility of our reverse-phase protein microarray assay was reported previously (18).…”

“…This technology is especially advantageous in clinical studies in which a large number of patient samples must be compared. We were able to identify a number of plasma/serum biomarkers with high potential for clinical application using 2DICAL (14)(15)(16)(17)(18). However, the direct analysis of plasma/serum proteins using 2DICAL remains technically challenging.…”

Proteome Variations in Pancreatic Stellate Cells upon Stimulation with Proinflammatory Factors

“…Although considerable advances have been made about understanding the molecular aspects of pancreatic cancer, there are still very few therapeutic modalities available (3,4), and they usually have only a limited effect because the tumors develop resistance shortly after initiation of chemotherapy.…”

“…The stroma consists of pancreatic stellate cells (PSCs) 3 , endothelial, inflammatory, and dendritic cells and also a dense proteinaceous matter composed mainly of extracellular matrix proteins such as collagen, fibronectin, and proteoglycans (6). Although stromal cells lack the genetic alterations observed in malignant pancreatic cells, they communicate with inflamed and tumor cells, driven by cytokines, chemokines, growth factors, and other inflammatory mediators, and contribute to tumor invasiveness and aggressiveness, resistance to chemotherapy, and metastasis formation (7)(8)(9)(10)(11).…”